What should be done and what should be avoided when comparing two treatments? [0.03%]
比较两种疗法时应注意什么和避免什么？
Florie Brion Bouvier,Raphaël Porcher
Florie Brion Bouvier
The preferred approach to compare two treatments is a randomized controlled trial (RCT). Indeed, randomization ensures that the groups compared are similar. Well-designed and well-conducted RCTs thus allow to draw causal conclusions on the ...
Richard M Szydlo
Richard M Szydlo
Research is based on trying to find answers to specific questions or to test hypotheses. Studies are thus undertaken to generate data which, with appropriate statistical methods, will help to determine the validity of the science under inve...
Designing and conducting a clinical trial in blood and marrow transplantation [0.03%]
造血干细胞移植的临床研究设计和实施
Michael J Martens,Yan Gao,Aniko Szabo
Michael J Martens
Clinical trials form the cornerstone of the science-based approach to improving patient outcomes. A trial needs to be designed and performed carefully to provide valid evidence to inform medical science and to protect the safety and well-be...
Pharmacogenomics in allogeneic hematopoietic stem cell transplantation: Implications on supportive therapies and conditioning regimens [0.03%]
同种异体造血干细胞移植中的药代组学：对支持疗法和预处理方案的意义
Sarah A Morris,D Grace Nguyen,Jai N Patel
Sarah A Morris
Allogeneic hematopoietic stem cell transplantation mortality has declined over the years, though prevention and management of treatment-related toxicities and post-transplant complications remains challenging. Applications of pharmacogenomi...
Financial toxicity in patients with leukemia undergoing hematopoietic stem cell transplantation: A systematic review [0.03%]
急性白血病患者造血干细胞移植的经济毒性系统评价研究
Orrin Pail,Thomas G Knight
Orrin Pail
Financial toxicity (FT) is a term used to describe the objective financial burden of cancer care including the associated coping behaviors used by patients and their caregivers. FT has been shown to result in both direct financial burdens a...
Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia [0.03%]
急性髓系白血病患者异基因移植后可测量的残留病变
Zoë C Wong,Laura W Dillon,Christopher S Hourigan
Zoë C Wong
The most common indication for allogeneic hematopoietic cell transplant (alloHCT) is maintenance of remission after initial treatment for patients with acute myeloid leukemia (AML). Loss of remission, relapse, remains however the most frequ...
Jing Ai
Jing Ai
Apheresis is an automated process to separate the whole blood of a patient or a donor, collect or remove specific blood components, and return the remaining back to the individual. Apheresis is an integral part of blood and marrow transplan...
Jai Singh
Jai Singh
Despite the rapidly evolving treatment landscape for acute myeloid leukemia (AML), allogeneic hematopoietic cell transplantation (allo-HCT) remains an important and potentially curative treatment option for many high-risk AML patients. Card...
Reducing barriers of access and care related to hematopoietic cell transplantation and cellular therapy: The mission-driven role of the national marrow donor program [0.03%]
造血干细胞移植和细胞治疗的准入和护理障碍的减少：全国骨髓捐献计划使命驱动作用的任务
Rafeek A Yusuf,Jaime M Preussler,Christa L Meyer et al.
Rafeek A Yusuf et al.
The treatment of malignant and nonmalignant hematologic disorders continues to benefit from significant scientific advancement and progress in the use of hematopoietic cell transplantation and cellular therapies. However, barriers associate...
"The state of the science" of childhood, adolescent and young adult Non Hodgkin Lymphoma (NHL) [0.03%]
儿童、青少年及年轻成人非霍奇金淋巴瘤（NHL）的科学研究现状
Mitchell S Cairo
Mitchell S Cairo